NeuroPace (NASDAQ:NPCE – Get Free Report) had its price objective cut by equities researchers at Cantor Fitzgerald from $21.00 to $12.00 in a report released on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 58.73% from the company’s current price.
Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of NeuroPace from a “hold” rating to a “sell” rating in a report on Saturday. Raymond James Financial set a $21.00 target price on shares of NeuroPace in a research report on Tuesday, September 15th. Guggenheim reissued a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Mizuho assumed coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective on the stock. Finally, HC Wainwright lowered their price objective on shares of NeuroPace from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Monday. Five research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $14.22.
View Our Latest Stock Report on NPCE
NeuroPace Stock Performance
Shares of NASDAQ:NPCE opened at $7.56 on Friday. The company’s 50 day moving average price is $13.21 and its two-hundred day moving average price is $14.75. NeuroPace has a 12-month low of $5.46 and a 12-month high of $19.60. The firm has a market cap of $259.49 million, a PE ratio of -13.50 and a beta of 1.98. The company has a quick ratio of 4.09, a current ratio of 5.26 and a debt-to-equity ratio of 5.15.
Institutional Trading of NeuroPace
Several hedge funds have recently modified their holdings of the stock. Entropy Technologies LP bought a new position in shares of NeuroPace during the 3rd quarter worth about $146,000. Diversified Trust Co acquired a new stake in shares of NeuroPace in the 3rd quarter valued at about $153,000. First Light Asset Management LLC raised its stake in NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after buying an additional 401,201 shares during the period. Bank of America Corp DE bought a new position in NeuroPace in the second quarter worth approximately $322,000. Finally, Man Group plc bought a new position in NeuroPace in the second quarter worth approximately $1,336,000. Institutional investors own 78.83% of the company’s stock.
NeuroPace Company Profile
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
See Also
- Five stocks we like better than NeuroPace
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
